|
Q&A: Brian Fagen
Brian Fagen is Executive Director of The Society of Pharmaceutical and Biotech Trainers with 30 years of experience in various positions inside and outside of the pharmaceutical industry. He talks to NGP about the role of the SPBT.
More >>
The change agent
Merck & Co., Inc. has been big pharma since the early 1900s – but recent years have seen it suffer its fair share of problems in the pipeline.
More >>
Marketing from big pharma to start-up biotech
Having recently made the move from pharmaceutical giant Pfizer to California-based biotech company, Cerimon Pharmaceuticals, Inc.
More >>
Great Expectations
The pharmaceutical business – once the envy of fellow industries for its year-on-year surging profits – has suddenly found itself staring at a crisis.
More >>
Highly evolved
How can Amgen continue its impressive revenue growth? By continuing on its course as an “R&D-driven” company, according to Willard Dere, Senior Vice President of Global Development and Chief Medical Officer.
More >>
Executive insight
NGP talks to Genzyme’s Fredric Vinick.
More >>
Eye On Business
What’s going on at LabCorp?
Talking with Dr. Andrew
Conrad, Chief Science Officer of National Genetics Institute, Global Head of
Esoterix Clinical Trials Services.
More >>
Multimedia Informed Consent: Can it help meet subject information needs?
More >>
Peptide microarrays in protein kinase and nuclear receptor research
Dr Rob Ruijtenbeek, VP Biological Sciences, PamGene International BV, Nieuwstraat 30,
5211NL ‘s-Hertogenbosch, The Netherlands
More >> |
Thought leader
Executive Interview
Talking with Christopher K. McLeod, President & CEO, 454 Life Sciences.
More >>
Using diseases to find cures
?Trying to obtain more information from diseased tissues will be an important step to improving the efficacy of drug development?
More >>
If we could just trust IT, what a healthy world it would be…
By Howard Asher, Founder and Chairman of the LSIT Global Institute
More >>
Taxonomies enhance pharmaceutical content intelligence
By Michael Hoey, CEO, Intellisophic
More >>
Monodisperse, discrete PEGs and
the future of drug development
“Control” is a strategic word in the world of
drug development and design.
More >>
Waiting in the wings
Chris Parry, chief executive of the Centre for High Performance Development (CHPD), claims that despite being just as good ? if not better ? than their male counterparts, women leaders struggle to climb beyond middle management.
More >>
Bridging the divide?
From the perspective of drug discovery scientists, knowing what related science is going on at different sites and how best collaboration may occur is key.
More >>
A voice for drug development
Jeff Bizzaro, Chairman of Bioinformatics.Org, speaks to NGP about the growing interest and emphasis on openness and transparency of information and practices in the industry and what changes are occurring.
More >>
The impact of CSOs on ROI
Facing a tougher operational environment in terms of competition and regulation, many companies are looking for strategic opportunities to leverage their investment in sales and marketing to achieve a better ROI.
More >> |
